About us

RusnanoMedInvest (RMI) is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology

RMI venture fund is currently managed by RMI Partners, a venture capital company focused on breakthrough developments of pharmaceutical products and technologies.  

RMI was created in March 2012. Initial funding - $380 million. The investor of RMI is RUSNANO, the nanotechnology investment, research and development arm of the Russian Government. 

  • localization of innovative life sciences and pharmaceutical technology in Russia;
  • creation and accumulation of  Russian-originated world-class expertise in the field of venture capital financing in Life Sciences;
  • stimulating the interest of investors and potential investors in the financing of Russian life sciences ideas, concepts and technologies.

All Partners

All Portfolio

MEDIA CENTER

  • Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

All news